ReviewFundamental & clinical pharmacology2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Review in Fundamental & clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundamental & clinical pharmacology · 2021Pooled it
- Polypharmacy among COVID-19 patients: A systematic review.Journal of the American Pharmacists Association : JAPhAPooled it
- COVID-19 management in patients with comorbid conditions.World journal of virology · 2025Review
- Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Predicting anti-SARS-CoV-2 activities of chemical compounds using machine learning models.Artificial intelligence chemistry · 2023Article
- Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.European journal of drug metabolism and pharmacokinetics · 2023Review
- Various Aspects of Non-Invasive Ventilation in COVID-19 Patients: A Narrative Review.Iranian journal of medical sciences · 2022Review
- Tools supporting polypharmacy management in Italy: Factors determining digital technologies' intention to use in clinical practice.Health science reports · 2022Article
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Impact of theInfection and drug resistance · 2022Article
- Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments.International journal of environmental research and public health · 2021Review
- Scoping insight on antiviral drugs against COVID-19.Arabian journal of chemistry · 2021Review
- ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO).European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.CNS drugs · 2021Review
- Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).Antimicrobial stewardship & healthcare epidemiology : ASHE · 2021Article
- SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments.Cell biochemistry and function · 2021Review
- Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.Fundamental & clinical pharmacology · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.